An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00335374. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Study identification
- NCT ID
- NCT00335374
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Type not available)
- Primary completion
- Sep 2008 (Actual)
- Completion
- Nov 2008 (Actual)
- Last update posted
- Feb 6, 2009
2007 – 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 419 | Birmingham | Alabama | — | — |
| 413 | Oceanside | California | — | — |
| 408 | Oxnard | California | — | — |
| 422 | New Haven | Connecticut | — | — |
| 403 | Boca Raton | Florida | — | — |
| 411 | Sarasota | Florida | — | — |
| 421 | Augusta | Georgia | — | — |
| 410 | Fort Wayne | Indiana | — | — |
| 417 | Lexington | Kentucky | — | — |
| 405 | Boston | Massachusetts | — | — |
| 420 | Boston | Massachusetts | — | — |
| 406 | Minneapolis | Minnesota | — | — |
| 412 | Raleigh | North Carolina | — | — |
| Site 402 | Dayton | Ohio | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00335374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2009 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.